PMV Pharmaceuticals, Inc. is an innovative precision oncology company headquartered in Cranbury, New Jersey, dedicated to the discovery and development of targeted small molecule therapies aimed at p53 mutations found in a range of cancers. By harnessing cutting-edge technology and in-depth insights into tumor biology, PMV seeks to transform cancer treatment paradigms with tumor-agnostic therapies, thus addressing significant unmet medical needs. The company's strategic focus on novel therapeutic options positions it to make a meaningful impact in the oncology landscape, offering hope to patients whose cancers express these critical mutations.